Loading...
Market
How many major U.S. health insurance plans will adopt Neffy by December 31, 2024?
2
Resolution / Starting Odds
None • 25%
1 to 3 major plans • 25%
4 to 6 major plans • 25%
More than 6 major plans • 25%
Health insurance plan coverage documents and announcements
Story
FDA Approves Neffy, First Needle-Free Epinephrine Treatment for Anaphylaxis
Aug 9, 2024, 04:52 PM
The U.S. Food and Drug Administration (FDA) has approved a new epinephrine nasal spray, neffy, developed by ARS Pharmaceuticals, as the first needle-free treatment for severe allergic reactions, including anaphylaxis. This approval, announced on Friday, marks a significant advancement in the treatment of allergic emergencies, offering an alternative to traditional epinephrine auto-injectors like the EpiPen. The nasal spray is approved for use in adults and pediatric patients who weigh at least 66 pounds. The FDA's decision is seen as a major step in improving accessibility and ease of use for individuals at risk of life-threatening allergic reactions.
View original story
Similar markets
All major insurers • 25%
Most major insurers • 25%
Some major insurers • 25%
Few or none • 25%
Increase Transparency • 25%
Improve Customer Service • 25%
Lower Premiums • 25%
No Significant Change • 25%
Yes • 50%
No • 50%
Increased security measures • 25%
Leadership restructuring • 25%
No major changes • 25%
Other changes • 25%
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%
0-5 • 25%
6-10 • 25%
11-15 • 25%
16 or more • 25%